FENNEC PHARMACEUTICALS INC (FENC)

CA31447P1009 - Common Stock

11.12  +0.03 (+0.32%)

After market: 11.12 0 (0%)

Fundamental Rating

2

Overall FENC gets a fundamental rating of 2 out of 10. We evaluated FENC against 592 industry peers in the Biotechnology industry. FENC may be in some trouble as it scores bad on both profitability and health. FENC does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

FENC had negative earnings in the past year.
In the past year FENC has reported a negative cash flow from operations.
In the past 5 years FENC always reported negative net income.
FENC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

FENC's Return On Assets of -106.25% is on the low side compared to the rest of the industry. FENC is outperformed by 80.78% of its industry peers.
Industry RankSector Rank
ROA -106.25%
ROE N/A
ROIC N/A
ROA(3y)-74.36%
ROA(5y)-71.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

FENC has a better Gross Margin (94.80%) than 96.09% of its industry peers.
The Profit Margin and Operating Margin are not available for FENC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

There is no outstanding debt for FENC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -11.18, we must say that FENC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FENC (-11.18) is worse than 80.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.18
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

FENC has a Current Ratio of 4.85. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
FENC's Current ratio of 4.85 is in line compared to the rest of the industry. FENC outperforms 51.19% of its industry peers.
A Quick Ratio of 4.40 indicates that FENC has no problem at all paying its short term obligations.
FENC has a Quick ratio of 4.40. This is comparable to the rest of the industry: FENC outperforms 49.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.85
Quick Ratio 4.4

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.10% over the past year.
EPS 1Y (TTM)6.1%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q77.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, FENC will show a very strong growth in Earnings Per Share. The EPS will grow by 41.67% on average per year.
Based on estimates for the next years, FENC will show a very strong growth in Revenue. The Revenue will grow by 185.94% on average per year.
EPS Next Y41.91%
EPS Next 2Y50.75%
EPS Next 3Y44.24%
EPS Next 5Y41.67%
Revenue Next Year2609.79%
Revenue Next 2Y683.08%
Revenue Next 3Y335.8%
Revenue Next 5Y185.94%

3.3 Evolution

2

4. Valuation

4.1 Price/Earnings Ratio

FENC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 45.31 indicates a quite expensive valuation of FENC.
Based on the Price/Forward Earnings ratio, FENC is valued cheaper than 94.90% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.79, FENC is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 45.31

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

FENC's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as FENC's earnings are expected to grow with 44.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.75%
EPS Next 3Y44.24%

0

5. Dividend

5.1 Amount

No dividends for FENC!.
Industry RankSector Rank
Dividend Yield N/A

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (3/28/2024, 8:09:07 PM)

After market: 11.12 0 (0%)

11.12

+0.03 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap300.68M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 45.31
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.25%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 94.8%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.85
Quick Ratio 4.4
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.1%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y41.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y